 Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 1 | 1 | | 1995 | 1 | 0 | 1 | | 1996 | 0 | 2 | 2 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2004 | 1 | 3 | 4 | | 2005 | 7 | 3 | 10 | | 2006 | 5 | 9 | 14 | | 2007 | 6 | 7 | 13 | | 2008 | 7 | 7 | 14 | | 2009 | 11 | 4 | 15 | | 2010 | 17 | 15 | 32 | | 2011 | 12 | 10 | 22 | | 2012 | 23 | 8 | 31 | | 2013 | 24 | 9 | 33 | | 2014 | 16 | 9 | 25 | | 2015 | 15 | 16 | 31 | | 2016 | 18 | 11 | 29 | | 2017 | 9 | 12 | 21 | | 2018 | 13 | 12 | 25 | | 2019 | 15 | 10 | 25 | | 2020 | 6 | 13 | 19 | | 2021 | 7 | 5 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Wu J, Galvan KJ, Bogard RD, Peterson CE, Shergill A, Crowe DL. DNA Double-strand Break Signaling Is a Therapeutic Target in Head and Neck Cancer. Anticancer Res. 2021 Nov; 41(11):5393-5403.
-
Yesilkanal AE, Johnson GL, Ramos AF, Rosner MR. New strategies for targeting kinase networks in cancer. J Biol Chem. 2021 10; 297(4):101128.
-
Pan T, Dan Y, Guo D, Jiang J, Ran D, Zhang L, Tian B, Yuan J, Yu Y, Gan Z. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. Eur J Med Chem. 2021 Nov 15; 224:113672.
-
Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennøe ØK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 07; 22(7):946-958.
-
Popat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, Griesinger F, Helland Å, Hochmair M, Pérol M, Bent-Ennakhil N, Kruhl C, Novello S. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 2021 07; 157:9-16.
-
Wang Z, Goto Y, Allevato MM, Wu VH, Saddawi-Konefka R, Gilardi M, Alvarado D, Yung BS, O'Farrell A, Molinolo AA, Duvvuri U, Grandis JR, Califano JA, Cohen EEW, Gutkind JS. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383.
-
Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. Eur J Cancer. 2021 05; 149:235-248.
-
Scarfone G, Fumagalli M, Imbimbo M, Ceruti T, Cribiù FM, Di Loreto E, D'Incalci M, Facchin F, Fontana C, Garassino MC, Peccatori FA, Persico N, Signorelli D, Zucchetti M. First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report. J Thorac Oncol. 2021 05; 16(5):873-877.
-
Berardi DE, Ariza Bareño L, Amigo N, Cañonero L, Pelagatti MLN, Motter AN, Taruselli MA, Díaz Bessone MI, Cirigliano SM, Edelstein A, Peters MG, Diament M, Urtreger AJ, Todaro LB. All-trans retinoic acid and protein kinase C a/ß1 inhibitor combined treatment targets cancer stem cells and impairs breast tumor progression. Sci Rep. 2021 03 15; 11(1):6044.
-
Lu P, Wang S, Franzen CA, Venkataraman G, McClure R, Li L, Wu W, Niu N, Sukhanova M, Pei J, Baldwin DA, Nejati R, Wasik MA, Khan N, Tu Y, Gao J, Chen Y, Ma S, Larson RA, Wang YL. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021 02 18; 11(2):39.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|